REG - ValiRx PLC - Shareholder Requisition Notice

ValiRxAnnouncement

04/03/2020 15:30

RNS Number : 0337F
  
ValiRx PLC
  
04 March 2020
  
 

ValiRx Plc
("ValiRx" or the "Company")
Shareholder Requisition Notice
 
London, UK, 4 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has received a letter from a group of shareholders (the "Letter") who hold in excess of 5% of the issued share capital of the Company, requiring that the Company convene, as soon as reasonably practicable, a general meeting, at which resolutions will be proposed to remove George Morris and Satu Vainikka as directors of the Company.
 
The Letter is a requisition under section 303 of the Companies Act 2006.
 
The Company is mindful that, pursuant to section 304 of the Companies Act 2006, the Company must post a notice convening a general meeting within 21 days from the date on which the requisition notice was received, and this general meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.
 
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
 
 
 
For more information, please contact:
 



ValiRx plc


Tel: +44 (0) 20 3008 4416
www.valirx.com




Kevin Alexander, Non-executive Director


Tel: +44 (0) 20 3008 4416




Tarquin Edwards, Head of Communications.


Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com














Cairn Financial Advisers LLP (Nominated Adviser) 
Liam Murray / Jo Turner / Ludovico Lazzaretti


Tel: +44 (0) 20 7213 0880














Allenby Capital Limited (Joint Broker)
Jeremy Porter / Alex Brearley (Corporate Finance)
Kelly Gardiner (Equity Sales)


Tel: +44 (0) 20 3328 5656
 














ETX Capital Limited (Joint Broker)
Thomas Smith


Tel: +44 (0) 20 7392 1568
 




Novum Securities Limited (Joint Broker)
Colin Rowbury


Tel: +44 (0) 20 7399 9400



 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCJIMATMTTMBFM